In This Article:
Over the last 7 days, the United States market has experienced a 3.0% decline, though it remains up by 18% over the past year with earnings forecasted to grow annually by 14%. In this context of fluctuating yet promising growth, identifying high growth tech stocks requires careful consideration of their potential for innovation and scalability in alignment with broader market trends.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 29.79% | 27.57% | ★★★★★★ |
| Travere Therapeutics | 28.04% | 65.55% | ★★★★★★ |
| Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
| AVITA Medical | 27.78% | 55.33% | ★★★★★★ |
| TG Therapeutics | 29.48% | 45.20% | ★★★★★★ |
| Bitdeer Technologies Group | 51.85% | 122.52% | ★★★★★★ |
| Clene | 61.16% | 59.11% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.67% | 58.73% | ★★★★★★ |
| Alvotech | 31.17% | 100.18% | ★★★★★★ |
| Lumentum Holdings | 21.24% | 119.37% | ★★★★★★ |
Click here to see the full list of 227 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Exact Sciences
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Exact Sciences Corporation is engaged in the development and commercialization of cancer screening and diagnostic test products, with a market capitalization of approximately $9.15 billion.
Operations: The company generates revenue primarily from its biotechnology segment, which contributed $2.76 billion. It focuses on cancer screening and diagnostic test products both domestically and internationally.
Exact Sciences, navigating through a challenging landscape marked by unprofitability, is poised for significant shifts with an expected revenue growth of 9.5% per year, outpacing the US market's 8.8%. Despite a substantial net loss of $864.59 million in Q4 2024, up from $49.77 million the previous year, the firm is optimistic about its future financial health, projecting annual revenues between $3.025 billion and $3.085 billion for 2025. This growth trajectory is supported by robust investments in R&D and strategic M&A activities aimed at enhancing its product offerings and market position in precision oncology and screening segments.
-
Delve into the full analysis health report here for a deeper understanding of Exact Sciences.
-
Evaluate Exact Sciences' historical performance by accessing our past performance report.
Bel Fuse
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Bel Fuse Inc. designs, manufactures, markets, and sells products that power, protect, and connect electronic circuits with a market capitalization of approximately $1.08 billion.
Operations: Bel Fuse Inc. generates revenue through three primary segments: Power Solutions and Protection, Connectivity Solutions, and Magnetic Solutions, with the Power Solutions and Protection segment contributing $245.55 million. The company's focus on designing and manufacturing electronic components allows it to serve a diverse range of industries by providing essential products that ensure the functionality of electronic circuits.